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Spinocerebellar ataxia 36 has been recently described in Japanese families as a new type of spinocerebellar ataxia with motor neuron
signs. It is caused by a GGCCTG repeat expansion in intron 1 of NOP56. Family interview and document research allowed us to
reconstructtwoextensive,multigenerationalkindredsstemmingfromthesamevillage(CostadaMorteinGalicia,Spain),inthe17th
century. We found the presence of the spinocerebellar ataxia 36 mutation co-segregating with disease in these families in whom we
had previously identiﬁed an  0.8Mb linkage region to chromosome 20p. Subsequent screening revealed the NOP56 expansion in
eight additional Galician ataxia kindreds. While normal alleles contain 5–14 hexanucleotide repeats, expanded alleles range from
 650 to 2500 repeats, within a shared haplotype. Further expansion of repeat size was frequent, especially upon paternal trans-
mission, while instances of allele contraction were observed in maternal transmissions. We found a total of 63 individuals carrying
the mutation, 44 of whom were conﬁrmed to be clinically affected; over 400 people are at risk. We describe here the detailed clinical
picture, consisting of a late-onset, slowly progressive cerebellar syndrome with variable eye movement abnormalities and sensori-
neuralhearingloss.Thereweresignsofdenervationinthetongue,aswellasmildpyramidalsigns,butotherwisenosignsofclassical
amyotrophic lateral sclerosis. Magnetic resonance imaging ﬁndings were consistent with the clinical course, showing atrophy of the
cerebellar vermis in initial stages, later evolving to a pattern of olivo-ponto-cerebellar atrophy. We estimated the origin of the
founder mutation in Galicia to have occurred  1275 years ago. Out of 160 Galician families with spinocerebellar ataxia, 10 (6.3%)
were found to have spinocerebellar ataxia 36, while 15 (9.4%) showed other of the routinely tested dominant spinocerebellar ataxia
types. Spinocerebellar ataxia 36 is thus, so far, the most frequent dominant spinocerebellar ataxia in this region, which may have
implications for American countries associated with traditional Spanish emigration.
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Introduction
The spinocerebellar ataxias (SCAs) are a heterogeneous group of
dominantly inherited neurodegenerative disorders, caused by
diverse mutation types and complex pathogenesis (Scho ¨ls et al.,
2004; Sequeiros et al., 2011). Large expansions of a GGCCTG
hexanucleotide repeat in the ﬁrst intron of NOP56 were recently
reported as the cause of a SCA and motor neuron disease, SCA36,
in 17 patients from 9 (3.6%) SCA families, originating from the
Japanese district of Chugoku (Kobayashi et al., 2011).
NOP56 encodes a component of the ribonucleoprotein complex
and plays a role in transcription and splicing processes. The rec-
ognition of large, non-coding expansions in an increasing number
of neuromuscular disorders (Matsuura et al., 2000; Sato et al.,
2009; Dejesus-Hernandez et al., 2011; Renton et al., 2011) has
raised interest in the pathogenic routes mediated by repetitive
RNA elements (Krzyzosiak et al., 2011). Although the pathogenic
mechanism is not well understood, the presence of RNA foci has
been related to sequestration of RNA-binding proteins (Daughters
et al., 2009; Sato et al., 2009; Kobayashi et al., 2011).
Furthermore, non-expansion mutations affecting RNA biogenesis
and regulation have also been associated with disorders of neuro-
development and neurodegenerative diseases affecting cerebellar
and motor pathways (Edvardson et al., 2007; Sreedharan et al.,
2008; Vance et al., 2009).
The Japanese patients with SCA36 showed a characteristic
phenotype, with spinocerebellar symptoms starting in the fourth
or ﬁfth decade, associated with signs of upper as well as lower
motor neuron involvement, manifested by skeletal muscle and
tongue atrophy and fasciculations. Although they were apparently
independent families, all mutation carriers showed the same
haplotype, suggesting a common founder and leading the authors
to hypothesize that SCA36 might be geographically limited to that
western region of Japan (Kobayashi et al., 2011).
At the time of the Kobayashi et al. (2011) publication, we found
the same mutation in two very large kindreds from a small Atlantic
coastal region in Northwestern Spain. These patients had an
autosomal-dominant, adult-onset and slowly progressive spinocer-
ebellar disease, which had been named ‘Costa da Morte’ (‘Coast
of Death’ in Spanish) ataxia (Arias et al., 2008), after the name of
that coastal area of Galicia. We now report a thorough clinical and
genetic characterization of the two original families, as well as
eight additional SCA36 kindreds from this region. This new muta-
tion represents the most frequent cause of SCA so far in Galicia.
Patients and methods
Patient recruitment and clinical
characterization
Apparently unrelated families with an autosomal dominant SCA had
been followed, since the early 1990s, at the Clinical University Hospital
of Santiago de Compostela. Clinical similarities and close regional
origin of the families led us to start an investigation to further delin-
eate the clinical and genealogical characteristics. These initial families
turned out to be branches of an extensive pedigree (Fig. 1, Family 1).
Subsequently, another large kindred, from the same area, segregating
a similar disease, was identiﬁed (Fig. 1, Family 2). Reconstruction of
multigenerational genealogies was achieved through recall of elder
Figure 1 Schematic representation of the ﬁrst six generations of the two largest SCA36 kindreds, Family 1 (left) and Family 2 (right);
black diamonds = deﬁnitely affected by examination and genetic analysis; white diamonds = deﬁnitely unaffected by examination and
genetic analysis or children of conﬁrmed unaffected individuals; question mark = individuals at risk, status unknown; inner
square = obligate carrier, not evaluated. Below each symbol the minimum number of subjects is indicated (i.e. for whom direct information
was obtained by family history and/or examination).
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and death certiﬁcates and property transmission certiﬁcates. The oldest
family members from whom documented references were available
lived in the 17th century.
The recruitment and study protocol was approved by the medical
research ethics committee from Galicia. Individuals who accepted to
participate in this study underwent a thorough neurological examina-
tion. The following workup was carried out: brain and spinal MRI,
complete blood count and metabolic screen, CSF analysis, EMG and
nerve conduction studies, audiometry, brainstem auditory evoked
potentials and somatosensory evoked potentials. Peripheral blood
was drawn and used for DNA puriﬁcation by standard methods. In
addition to Families 1 and 2, DNA samples from 158 index cases with
SCA, all from Galicia, were available for this study. From the total of
160 ataxia kindreds, 47 families segregated the disease in an auto-
somal dominant manner, 38 had a family history of ataxia but no clear
inheritance pattern, 34 were reported as sporadic cases, and no family
information was available for 41. All these patients had previously
been screened for Friedreich ataxia, SCA1, SCA2, Machado–Joseph
disease/SCA3, SCA6, SCA7, SCA12, SCA17, dentatorubropallidoluy-
sian atrophy and fragile-X-associated tremor ataxia syndrome
(M. Garcı ´a-Murias et al., unpublished data).
Genotyping and linkage analysis
In a ﬁrst phase, DNA samples from 68 individuals belonging to
Families 1 and 2 were genotyped for a panel of 1000 microsatellite
markers with average spacing of 4 cM along the genome (DeCode
Genetics). Out of 31 repeat motives identiﬁed in the region of interest,
12 were found to be polymorphic and used for reﬁnement of linkage
analysis and haplotype reconstruction (Supplementary Tables 1 and 2).
Subsequently, we selected 241 single nucleotide polymorphisms (SNPs)
spanning the linkage region using information in dbSNP version 130
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and HapMap (http://
hapmap.ncbi.nlm.nih.gov/). In this tier, 87 individuals were genotyped
together with those from Phase 1. Obligate carriers and healthy
spouses were included in the haplotype analysis to establish phase.
The iPLEX assay for MassARRAY platform (Sequenom Inc.) was
used for genotyping in multiplex format, and the analysis software
(TYPER Analyzer) was used to translate the observed mass into a
genotype for each reaction. Parametric two-point and multipoint link-
age analyses, and haplotype reconstruction, were performed using the
software FastLink v4.1 and GeneHunter v2.1r5, implemented by the
easyLINKAGE V5.05 platform (Lindner et al., 2005), under the
assumptions of autosomal dominant inheritance, complete penetrance,
a disease allele frequency of 0.00001 and equal allele frequencies for
marker loci.
Haplotype reconstruction and
estimation of mutation age
Merlin 1.1.2 was used for the inference of combined—microsatellite
and SNP—haplotypes (Abecasis et al., 2002). Where family data were
not informative, we used PHASE 2.1.1 (Stephens et al., 2001;
Stephens and Donnelly, 2003) specifying the known haplotypes. The
age of the most recent common ancestor of mutation carriers was
estimated using a likelihood-based method with the ESTIAGE program,
based on the length of the haplotype shared on each side of the
disease locus (Genin et al., 2004). For that purpose, 14 microsatellites
and one SNP spanning 4.98Mb around the mutation were analysed in
10 mutation carriers representing each family. An attempt to date the
mutation was also performed with DMLE+2.3 (http://dmle.org). The
software implements a Bayesian method based on the observed link-
age disequilibrium between a disease mutation and linked markers to
infer the age of the mutation (Reeve and Rannala, 2002; Rannala and
Reeve, 2003). Haplotypes in control individuals were estimated using
PHASE, and the relative position of the mutation was set within the
haplotype. Population growth rates of 0.05 and 0.07 were used for
the calculations, based on previous data for European populations and
on Galician historic census (http://www.ine.es/). Two alternative pro-
portions of carrier chromosomes were estimated, considering a disease
prevalence of 1:10000 or 1:20000.
Mutation screening and structure of the
NOP56 intronic repeat
Mutation screening was carried out in patients and controls. Primer
pairs were designed to polymerase chain reaction (PCR)-amplify and
sequence all coding exons in 21 known and predicted genes, as well as
nine small non-coding RNAs in the region, using an ABI3730 auto-
matic analyser. The STADEN software (Staden, 1996) was used to
analyse electrophoretic traces. To investigate potential deletions or
multiplications, we carried out a high-throughput genotyping of
affected and non-affected individuals, with the Affymetrix 6.0
genome-wide array, which included 277 SNPs between the limits of
recombination. Copy number ﬁles (CNCHP) were generated with the
Genotyping Console and visualized on the Affymetrix Chromosome
Analysis Suite. For a ﬁner level of resolution, a 60000-oligonucleotide
array was custom-designed (qGenomics) covering 1.9Mb and
affected/non-affected sample pairs were hybridized. The Agilent
Genomic Workbench software (Agilent Technologies) was used to
analyse the data.
In addition, 31 sequence elements of 3–7 bp and at least four repeat
units were identiﬁed in the region and ampliﬁed with ﬂanking primers
to screen for potential expansions. Two primer pairs were used to
amplify the NOP56 intron 1 region, one of them ﬂanking the
GGCCTG repeat only, while the other pair included a 6-bp
CGGGCG insertion/deletion (rs28970277, NM_006392.2:c.3+22_3+
27delCGGGCG) 44bp upstream from the hexanucleotide repeat.
Fluorescent triplet repeat primed polymerase chain reaction (TP-PCR)
(Warner et al., 1996) was carried out on 25ml reactions, as follows:
60ng of DNA, 200mM of each dNTP, 1.5mM MgCl2,5ml of 360 GC
Enhancer (Applied Biosystems), 1.25U AmpliTaq Gold 360 DNA
Polymerase and 1  buffer (Applied Biosystems), 0.8mM reverse uni-
versal primer, 0.8mM forward primer and 0.08mM repeat-speciﬁc
primer (Kobayashi et al., 2011). The reaction mixture was denatured
at 95 C for 10min and subjected to 40 cycles (95 C   1min,
63.5 C   1min, 72 C   4min, adding 10s each cycle). The mixture
was maintained at 72 C, for 10min, for ﬁnal extension. Ampliﬁed
fragments were separated in an ABI3730 analyser and alleles were
determined with Fragment Analysis software. Both standard and
TP-PCR were carried out in 136 individuals from Families 1 and 2.
These analyses were then performed in another 158 index cases
with SCA from Galicia. Subsequently, 23 additional individuals from
Families 3–10 were also analysed, as well as 214 Spanish patients with
spastic paraplegia of unknown aetiology and 234 Galician healthy in-
dividuals aged 465 years. To establish the variability in the structure
of non-expanded SCA36 alleles, homozygous samples were sequenced
by standard Sanger sequencing. We also sequenced the PCR products
obtained through standard ampliﬁcation from expansion carriers, thus
characterizing the smaller, non-expanded allele in each patient. All
primer sequences are available in Supplementary Table 1.
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Detection and approximate assessment of the number of expanded
GGCCTG repeats in affected individuals was carried out by Southern
blot. Genomic DNA (10mg) was digested with BsmI (New England
Biolabs) according to the manufacturer’s instructions. Digestion prod-
ucts were separated by electrophoresis on a 0.8% agarose gel, depuri-
nated with 0.25M HCl, denaturized with 0.4M NaOH and transferred
with 10  SSC (saline-sodium citrate) buffer onto a Hybond-N
+ nylon
membrane (GE Healthcare). DNA was immobilized on the membrane
by UV cross-linking. A 715-bp probe for hybridization was synthesized
from genomic DNA, by PCR, using the Expand High Fidelity PCR
System (Roche Applied Science) and primers ﬂanking exons 2 and 3
of NOP56 (Supplementary Table 1). The probe was labelled with
[-32P]-dCTP with a speciﬁc activity of 3000Ci/mmol (Perkin
Elmer), using the Prime It II Random Primer Labelling Kit (Agilent
Technologies). Hybridization with the labelled probe was carried out
overnight, at 65 C, and signal detection was performed by X-ray ﬁlm
exposure.
Statistical analysis
The size of the expanded repeat was compared between subsequent
generations for 27 mutated alleles, in Families 1 and 2, both globally
and according to the gender of the transmitting parent. Kaplan–Meier
analyses were used to estimate the inﬂuence of allele size on
disease-onset age. Onset age was compared between groups of
patients with allele size of  600–850, 850–1200 and 41200 repeats.
Log-rank test statistics were used to determine whether the Kaplan–
Meier curves differed between subgroups. Mean onset age per
generation was also analysed. Statistical signiﬁcance was deﬁned as
P50.05, and calculations were performed with the statistical software
package SPSS version 15.0 for Windows (SPSS Inc.).
Results
Linkage to chromosome 20p and
mutation screening
Two large kindreds with an autosomal dominant form of SCA
originated from the most Northwestern part of Galicia (Spain),
an area with, for many years, difﬁcult access both by sea and
by road. Extensive family interviews and document studies allowed
us to reconstruct two large pedigrees with 673 individuals (Family
1) and 676 individuals (Family 2), spanning seven generations, and
represented in Fig. 1. After genome-wide linkage analysis, a max-
imum two-point LOD (log10 of odds) score of 9.8 was obtained
for marker D20S842. Subsequent microsatellite and SNP genotyp-
ing placed the critical interval between the telomeric marker
rs2422752 and the centromeric marker D20S181, spanning
 2 cM and  0.8Mb. No point mutations co-segregating with
the disease were found in exonic regions of 30 genes and
microRNAs within the candidate region by direct sequencing of
affected and unaffected subjects. The variants identiﬁed are avail-
able as Supplementary Table 2. Single nucleotide changes without
an ‘rs’ number were submitted to dbSNP. Speciﬁcally, we did not
ﬁnd mutations in PDYN and TGM6, which lie within the linkage
region and have been reported as mutated in SCA23 and SCA35,
respectively. Dosage analysis by comparative genomic hybridiza-
tion array and Affymetrix 6.0 genome-wide SNP array disclosed
no aberrations.
Unstable NOP56 hexanucleotide
expansion in families with ataxia
Mendelian inconsistencies in allele transmission within nuclear
families were observed upon fragment length analysis of a
GGCCTG repeat in intron 1 of NOP56, while no patterns suggest-
ive of repeat expansion were detected in additional repetitive
elements in the region. A TP-PCR pattern suggesting the presence
of an expansion was present in all affected members of Families
1 and 2; a similar pattern was then observed in eight additional
index cases from a cohort of patients with SCA from our region
(Fig. 2A). Ten out of 160 (6.3%) index cases from our cohort of
families with SCA showed a SCA36 expansion. In all, 63 individ-
uals from these 10 families tested positive by TP-PCR. Southern
blot analysis was possible in 34 samples and conﬁrmed the pres-
ence of very large abnormal alleles in all cases. While the normal
restriction fragment is of 2.9kb with our protocol, expanded
alleles ranged from 6.8 to  18kb, corresponding to  650–2500
additional hexanucleotide repeat units (Fig. 2B).
(GGCCTG)n size distribution in ataxia,
spastic paraplegia and healthy
individuals
No instances of the NOP56 mutation were detected among 234
healthy Galician controls. Likewise, no SCA36 expansions were
present in 214 Spanish patients with spastic paraplegia, a group
of genetically heterogeneous degenerative motor neuron
disorders. To characterize normal variation of the NOP56 intron
1 repeat, allele size distribution was analysed in the three samples
studied (Fig. 3). The number of hexanucleotide repeats in normal
alleles varied from 3 to 14, with the nine-repeat allele being the
most frequent. The repeat size distribution and allele frequencies
were similar in normal alleles of SCA, patients with spastic para-
plegia and in healthy controls.
Clinical characteristics of SCA36 in
Costa da Morte families
A total of 144 subjects belonging to Families 1 and 2 were clin-
ically examined. Once the SCA36 mutation was identiﬁed, eight
additional patients with SCA carrying the same mutation were
detected in our cohort of undiagnosed ataxia index cases, and
23 other members of these families were recruited for further
clinical and genetic characterization in the context of the present
research. The main clinical features of 44 affected people (20
males, 24 females, mean age at examination: 63.8 years) are
summarized in Table 1. In brief, the typical picture is one of gait
imbalance, starting from the late 40s to the mid-50s. A few pa-
tients reported initial symptoms as episodes of vertigo, dizziness or
blurred vision. Almost all noticed progressive hearing loss at onset,
some even before the balance problems. Difﬁculties with speech
1426 | Brain 2012: 135; 1423–1435 M. Garcı ´a-Murias et al.were noticed generally a few years after disease onset, although
some patients reported simultaneous onset of both ataxia and
dysarthria. Midline-gait ataxia was the most prominent and invari-
able feature, with limb ataxia generally of lesser degree and more
pronounced in lower than upper limbs. Abnormal eye movements
were common, mostly consisting of slow saccades, slow pursuit
and ﬁxation instability. Some patients also had vertical or horizon-
tal gaze limitation, with certain quality of ocular motor apraxia and
a mild eyelid ptosis in a few cases. The dysarthria had mostly
cerebellar, but also a somewhat pseudobulbar quality. Horizontal
and vertical nystagmus was only occasionally seen. Almost all pa-
tients showed involuntary worm-like tongue movements suggest-
ive of fasciculations or myokymia, and some had mild tongue
atrophy. Although with disease progression some patients had
mild dysphagia, especially for liquids, swallowing was not affected
in a degree comparable with other diseases affecting motor
neurons such as amyotrophic lateral sclerosis. Furthermore, no
fasciculations or signiﬁcant muscle atrophy, indicative of otherwise
typical lower motor neuron disease, was detected in other
facial muscles or in other body segments. Mild pyramidal signs
were common, generally limited to brisk tendon reﬂexes and
occasional Babinski sign, although an increased muscle tone in
the lower limbs was also present in some patients (Table 1).
Most patients were cognitively intact, and in only two cases
could we observe mild cognitive decline of frontal-subcortical
characteristics.
Brain MRI, available for nine patients of different ages, showed
superior cerebellar vermis atrophy in the younger cases, diffuse
cerebellar atrophy in patients some years into the disease course
and a pattern of olivo-ponto-cerebellar atrophy without abnormal
T2-weighted image MRI signal in the pons or medulla in older
patients (Fig. 4). Cortical brain atrophy was present only in
Figure 2 Mutation analysis in patients with SCA36. (A) PCR ampliﬁcation of the (GGCCTG)n in a nuclear family showing the lack of
transmission of a normal size allele from the affected parent to the affected child, as well as a repeat expansion pattern in both by TP-PCR.
AC = affected child; AP = affected parent; UC = unaffected child; UP = unaffected parent. Genotypes are indicated on the right end of
each panel. (B) Southern blot analysis of four unaffected (left) and four affected subjects (right).
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lesions were generally observed, with the exception of one patient
who also had high blood pressure. Cell count, proteins and glu-
cose in the CSF were normal in four patients in whom it was
examined. Audiometry studies, carried out in six patients,
showed moderate to severe bilateral sensorineural hearing loss,
with over 40dB drop beyond 2500Hz. Brainstem evoked poten-
tials in the same cases disclosed absent or severe decrease of
waves I and II. Somatosensory evoked potentials performed in
ﬁve patients (three males, two females, ages 60–80 years) invari-
ably showed prolonged latency and low amplitudes upon stimulus
of the lower limbs, while normal in the upper limbs.
Electroneuromyography, performed in nine cases at ages 57–90
years, showed normal sensory and motor nerve parameters.
Invariably, signs of denervation (ﬁbrillations, positive waves)
were limited to the tongue, without evidence of spontaneous
muscle activity in other territories, thus suggesting affectation lim-
ited to the second motor neurons in the lowest portion of the
brainstem.
Repeat instability and
genotype–phenotype correlation
The size of the mutant allele differs often within nuclear families.
Analysis of the available Southern blot results for the two largest
kindreds showed that the expansion tends to increase upon trans-
mission in successive generations. Mean allele size increased from
7.4 to 9.2kb when comparing three successive generations. While
the average allele size was of 7.9kb in patients who received it
from their mother, it was 9.4kb when received from an affected
father (Table 2). In three mother–child pairs where the mutant
allele could be measured, there was an increase of 0.4kb in one
case, while a contraction of 5–8kb was observed in the other two.
On the other hand, the increase of allele size in seven available
father–child transmissions was 1.6kb on average, with one case of
invariable allele size, but no case of allele contraction among these
transmissions. In Family 1, the largest pedigree we studied, mean
age of onset was 56.3 years in generation IV and 52.4 years in
generation V. While observation of single instances suggested an
Figure 3 (A) Allelic distribution of NOP56 intron 1 GGCCTG hexanucleotide repeat in patients with SCA, patients with spastic paraplegia
(SPG) and control individuals. Sequence structures identiﬁed for normal size alleles are represented inside the boxes, the total number of
alleles sequenced with each structure indicated in brackets. Insertions (INS) and deletions (DEL) before the repeat sequence indicate alleles
with the upstream CGGGCG indel polymorphism insertion or deletion, respectively. (B) Schematic representation of NOP56 exons 1 and
2, and intron 1, indicating the relative positions of the GGCCTG repeat expansion mutation and the CGGGCG indel polymorphism
(rs28970277).
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‘Costa da Morte’ ataxia is SCA36 Brain 2012: 135; 1423–1435 | 1429earlier onset in carriers of larger alleles, this association was not
statistically signiﬁcant by Kaplan–Meier analysis (data not shown).
Carriers of larger alleles also had a tendency to show more severe
symptoms, especially in gait ataxia, and a mild impairment of
executive function.
Estimation of mutation age of
the founder repeat
All 63 subjects from the 10 kindreds with the NOP56 hexanucleo-
tide expansion carried the same core haplotype, suggesting that a
founder chromosome was responsible for the Galician cases.
Table 3 shows the overlap between 10 distinct extended haplo-
types identiﬁed in the study families. The age of the most recent
common ancestor was estimated by ESTIAGE in 25 generations
(95% conﬁdence interval, 16–41). Given that from the deduced
haplotypes some families seemed to be more closely related, we
sequentially removed each of the haplotypes from the analysis,
with estimates varying from 24 to 29 generations. Considering
an intergenerational time interval of 25 years, this ancestor
would have lived 625 years ago (95% conﬁdence interval,
400–1025). Estimates of the mutation age using the DMLE+2.3
software using different demographic and disease prevalence par-
ameters are shown in Fig. 5. The estimated mutation age ranged
from 37 to 74 generations, the lower and upper limits for these
estimates being 23 and 122 generations, respectively. Given a
disease prevalence of 1:10000 and a population growth rate of
r = 0.07, the origin was calculated to have occurred 51 gener-
ations ago (95% credible set ranging from 31 to 89 generations).
According to this, the founder effect would have been more likely
 1275 (775–2225) years ago.
Discussion
We report here the presence of the NOP56 intronic GGCCTG
hexanucleotide expansion in two large families from Costa da
Morte (Arias et al., 2008) presenting with an SCA phenotype
that we had previously linked to chromosome 20p, and eight
Figure 4 Brain T1-weighted MRI images from three patients with SCA36 of different ages. Saggital and axial images are shown from
patients aged 52 (A and B), 65 (C and D) and 85 (E and F) years. The disease affects manly the superior vermis in younger patients, later
also affecting other cerebellar areas and the brainstem.
Table 2 Comparison of expanded allele size by generation
and gender of the transmitting parent in 27 expanded
alleles from Families 1 and 2
Generation Allele size
total
Paternally
transmitted
alleles
Maternally
transmitted
alleles
IV 7.4   0.4 (2) 7.8 (1) 7 (1)
V 8.8   1.1 (16) 9.3   1.3 (10) 7.8   0.6 (6)
VI 9.2   0.8 (9) 9.5   0.6 (6) 8.4   1.0 (3)
Global 8.8   1.1 (27) 9.4   1.1 (17) 7.9   0.8 (10)
Number of alleles in each category are indicated in brackets. Allele sizes are
expressed in kilobase as mean   SD.
1430 | Brain 2012: 135; 1423–1435 M. Garcı ´a-Murias et al.Table 3 Representative haplotypes in patients from the ten SCA36 families of the present study
Marker Distinctive haplotypes Physical
position (bp)
Recombination
fraction ()
Frequency
shared allele
in controls F.9 F.10 F.6 F.3 F.1 F.2 F.5 F.8 F.7 F.4
D20S117 5 5 5 10 99585 5 655092 0.0493 0.1522
D20S199 3 33 33223 12 12 1093988 0.0384 0.1379
D20S906 5 5 5 554445 5 1505567 0.0282 0.0833
REP-14 9 99 999991 1 1933358 0.0175 0.1964
D20S113 11 1 1111 2 1 1 2035488 0.0149 0.6296
rs2422752 T TT T T T [T] [T] C C 2360990 0.0068 0.2353
REP-19 2 22 2222 2 2 2 2526316 0.0027 0.0345
M 2633379
D20S842 12 12 [12] 12 12 12 12 12 12 12 2686204 0.0013 0.0200
D20S181 2 2 12 4 2 2 2 2 2 3172512 0.0135 0.1667
D20S473 45 5 4444 4 4 4 3465436 0.0208 0.4167
D20S482 5 6 63 5 5 6 3 3 3 4506248 0.0467 0.0667
D20S97 22 2 524865 5 4524153 0.0471 0.0167
D20S895 2 55 654 [5] 8 6 7 5086623 0.0610 0.0517
D20S849 56 6751557 1 5194034 0.0637 0.1071
D20S882 4 44 844434 4 5635098 0.0744 –
Framed haplotype indicates the common haplotype shared by all patients. Shaded haplotypes correspond to haplotypes shared by subsets of patients and part of a
presumed ancestral haplotype. Allelic phase inferred by PHASE is shown in italics. In brackets are those alleles not genotyped, but inferred by PHASE. M = mutation. Physical
position in base pairs according to GRCh37/hg19. Recombination fraction between each marker and the mutation was computed using Kosambi mapping function,
considering a correspondence of 2.5 cM per Mb for the region studied. Frequency of the shared allele for each marker was estimated from 30 population-matched controls.
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Figure 5 Result from the DMLE analysis showing posterior probability density of the mutation age for different population growth rates
(r = 0.05, r = 0.07) and different proportions of mutation bearing chromosomes sampled (f = 0.037, f = 0.074). The dashed lines cor-
respond to the 95% credible set of values.
‘Costa da Morte’ ataxia is SCA36 Brain 2012: 135; 1423–1435 | 1431additional kindreds also from the Spanish region of Galicia. In a
retrospective analysis of our total cohort of 160 SCA index cases,
we observed that 10 (6.3%) had SCA36, 7 (4.4%) had an SCA2
mutation, 3 (1.9%) had SCA1, 3 (1.9%) SCA3 and 2 (1.3%) had
SCA7. While SCA3 is accounted for as the most frequent SCA
type worldwide (Silveira et al., 1996; Tang et al., 2000;
Sequeiros et al., 2011), the frequency of SCA36 in Galicia exceeds
that of any of the other SCA types. Further, 480% of the
Galician patients with SCA remain without a genetic diagnosis.
Previous studies in Spanish patients showed a similar frequency
of SCA2 and SCA3, each representing between 15% and 30%
of all autosomal dominant ataxia (Pujana et al., 1999; Infante
et al., 2005). If only families with deﬁnite dominant inheritance
were considered, SCA36 would represent 21.3% of our series.
One of the SCA36 index cases was a 69-year-old patient,
whose parents had died at the age of 80 and 63 years, respect-
ively, without having shown signs of the disease. Also, no add-
itional affected individuals were recognized even after thorough
family interview, suggesting that SCA36 should be considered also
in the diagnosis of apparently sporadic ataxia cases. Two genes,
PDYN and TGM6, within this same chromosomal region have
been associated with SCA23 and SCA35, respectively (Bakalkin
et al., 2010; Wang et al., 2010). We screened the coding
region of these genes and did not detect mutations.
Our results conﬁrm, in the Spanish population, the
co-segregation of the GGCCTG hexanucleotide expansion in
NOP56 with SCA, as well as the absence of expansions in
normal individuals. Lack of co-segregation of the mutation with
the disease and the presence in normal individuals in other SCAs,
such as SCA31 (Ishikawa et al., 2011), challenge the interpretation
of the pathogenic role of some expansions and strengthen the
importance of our ﬁndings. We detected a total of 63 individuals
with an SCA36 mutation, while over 400 people belong to any of
the at risk family branches. These data have crucial implications for
the establishment of diagnostic and follow-up protocols for the
late-onset ataxias in the region of Galicia. The availability of a
robust TP-PCR protocol, together with the presence of a charac-
teristic associated haplotype, will facilitate the molecular diagnosis
in this population. The question now remains whether SCA36 will
turn out to be a frequent cause of ataxia in other regions of Spain
and/or in Portugal, as well as in other Caucasian populations,
especially those associated with traditional Spanish emigration.
From a clinical standpoint, the Spanish patients with SCA36
present with a late-onset spinocerebellar syndrome, with truncal
ataxia as the foremost manifestation. Disease progression was
slow, most of the patients remaining ambulant for 15–20 years
after onset and longer. Appendicular ataxia, manifesting as dys-
metria, uncoordinated alternating movements and overshoot, was
less prominent than gait ataxia. A diverse combination and sever-
ity of eye movement abnormalities were also present in the pa-
tients. While no hearing impairment was reported in the Japanese
SCA36 families (Kobayashi et al., 2011), a characteristic pattern of
sensorineural deafness was detected in all Spanish patients exam-
ined, with audiometry showing a moderate to severe loss of
540dB over 2500Hz. Although hearing loss may be present in
several ataxia types (Ikeda et al., 2011), the consistency of this
feature in our patients suggests it may be a distinctive clinical
aspect of the disease, at least in Spain, and should point to the
possibility of SCA36 when present in ataxia cases. Similar to the
cases reported by Kobayashi and collaborators (2011), numerous
Galician patients with SCA36 had tongue fasciculations. Although
these signs of denervation were more prominent as the disease
progressed, functional consequences of lower motor disease on
swallowing and speech were not signiﬁcant. Our patients had
relatively well preserved swallowing throughout the disease
course, i.e. dysphagia was mild and not different from what is
generally seen in other SCAs. Kobayahi et al. (2011) also noted
the lack of signiﬁcant dysphagia in their patients, in spite of the
tongue fasciculations and atrophy. Also, further clinical or neuro-
physiological signs of lower motor neuron involvement were not
evident in our cases. Mild upper motor neuron signs were gener-
ally present. Action myoclonus and myokymia in the facial muscles
can be observed in some forms of olivopontocerebellar atrophy
and in these cases enhanced long-latency facial reﬂexes can some-
times be demonstrated (Valls-Sole ´ et al., 1994). We did not notice
myokymia, twitching or other abnormal movements in perioral or
other craniofacial muscles in the SCA36 cases, and only one
patient had myoclonic jerks of the neck and trunk muscles
(Table 1). Electrophysiological study of brainstem function will
be useful to further detail the characterization of the SCA36
phenotype in the future. No signiﬁcant sensory alteration was de-
tectable upon clinical examination of most of the patients. Only
very mild hypopallesthesia was present in one of the oldest indi-
viduals examined and was considered unspeciﬁc. Sensory nerve
conduction studies of the sural nerve were normal, whereas
lower limb somatosensory evoked potentials were abnormal in
all individuals in whom they were examined, demonstrating affect-
ation of the central sensory tracts. This may suggest that SCA36
could be another central distal axonopathy involving the sensory
system (Thomas et al., 1984). Further somatosensory evoked
potentials of additional patients, as well as electrophysiological
evaluation of the pyramidal tracts will be needed to demonstrate
this hypothesis. Cognition was normal in most patients, only two
showing a mild impairment, with a frontal-subcortical pattern, and
a mild degree of emotional lability.
A common characteristic in many neurodegenerative
disorders associated with genomic expansions is clinical anticipa-
tion. Kobayashi et al. (2011) found no evidence of anticipation in
17 patients from nine families with a mean onset age of 52.8
years. We observed a tendency of the expanded SCA36 alleles
to increase in size upon transmission (Table 2), more frequently
in paternal transmission, as occurs in SCA10 (Matsuura et al.,
2004), as well as in (CAG)n expansions, where a slight maternal
contraction bias as opposed to a paternal expansion bias of the
mutant has been reported (Aziz et al., 2011). There were several
instances of an earlier onset and worse symptoms when compared
with their affected parent, and the mean onset age was slightly
lower in the ﬁfth generation (52.4 years) than in the fourth gen-
eration (56.3 years) in Family 1, suggesting a tendency towards
clinical anticipation. A signiﬁcant correlation between allele size
and onset age was not derived, however, from our data. These
data should be taken cautiously, since both allele size and accur-
ate age of disease onset are difﬁcult to establish, as is usually the
case with most late-onset neurodegenerative diseases where
1432 | Brain 2012: 135; 1423–1435 M. Garcı ´a-Murias et al.ascertainment biases are also likely. Therefore, more extensive and
detailed studies are needed to fully address this question.
Patients with SCA36 show signs of both upper and lower motor
neuron dysfunction. Furthermore, SCA and spastic paraplegia are
two groups of neurodegenerative disorders with a signiﬁcant
degree of clinical and genetic overlap. Thus, we looked for expan-
sions in 214 patients with pure or complicated forms of spastic
paraplegia. No GGCCTG repeat expansions were seen in this
group or in 234 healthy Galician controls. This is consistent with
the report by Kobayashi et al. (2011) that no SCA36 mutations
are found in patients with amyotrophic lateral sclerosis or demen-
tia. Together, these results suggest that the pathogenic effects of
the large expansions in NOP56 may be more speciﬁc on cerebellar
function. Interestingly, a hexanucleotide repeat expansion in the
ﬁrst intron of C9ORF72 was recently reported as the most
common genetic cause of frontotemporal dementia and amyo-
trophic lateral sclerosis, another neurological disorder with degen-
eration of motor neurons (DeJesus-Hernandez et al., 2011;
Renton et al., 2011).
The size of expanded alleles in the Spanish families ranged from
 650 to 2500 repeats, a wider range than reported by Kobayashi
et al. (2011) for the Japanese SCA36 expansions (1700–2300
repeats). On the other hand, the normal GGCCTG repeat size
ranged from three to eight in 300 Japanese controls, while the
normal size range in our population was also slightly broader
(3–14), the nine-repeat allele being the most abundant.
However, because it is not clear whether the primers used by
Kobayashi et al. (2011) for ampliﬁcation of the repeat also include
the nearby indel, ranges of allele size may not be comparable. We
then characterized the structure of non-expanded alleles by
sequencing, and showed that non-expanded alleles in our popu-
lations consist of diverse combinations of an imperfect repeat
(RGCCTG)-(GGCCTG)n-(CGCCTG)n, with or without a CGGGCG
deletion 44bp upstream of it (Fig. 3).
The SCA36 mutation lies within a common haplotype in all our
patients, suggesting a founder origin, which is further supported
by the fact that the largest kindreds (Families 1 and 2) originated
from an isolated coastal area. We have traced back the origin of
the Galician SCA36 expansion to  51 generations ( 1275 years
ago), although these estimates partly depend on parameters that
are difﬁcult to determine, such as population growth rate and
proportion of disease-bearing chromosomes ascertained in the
study (Fig. 5). The results obtained with ESTIAGE and DMLE are
consistent between them and with the fact that the age of the
most recent common ancestor has to be equal to or less than the
time in history at which the mutation arose (Rannala and
Bertorelle, 2001). The nine SCA36 families reported in Eastern
Japan also shared a common haplotype, which is not directly
comparable with Galician haplotypes with the marker information
available (Kobayashi et al., 2011). The haplotype shared by the
Japanese patients is larger (1.8Mb) than the Galician SCA36
haplotype (0.8Mb), suggesting the former might have a more
recent origin. It will be interesting to investigate whether the
mutation found in Japanese patients and that in Spain have
a common origin, such as is the case for the SCA3/Machado–
Joseph disease CAG expansion, where a common original
chromosome has been found in most families worldwide
(Gaspar et al., 2001). Founder mutations have also been described
for other SCAs and populations (Verbeek et al., 2004; Sequeiros
et al., 2011). The Asian origin for an ancestral Machado–Joseph
disease/SCA3 mutation has been shown (Martins et al., 2007);
Portuguese dentatorubropallidoluysian atrophy families also share
a common ancestral haplotype with Japanese patients (Martins
et al., 2003). A similar relationship with Japan could apply to
Galicia. Nevertheless, independent mutational events for the
Galician and Japanese SCA36 expansions are also possible. It
should also be emphasized that our region has traditionally been
associated with emigration towards Latin America, especially
during the 19th and 20th centuries. In fact, many family members
of the kindreds in this study had reportedly emigrated to
Argentina, Uruguay, Chile and Mexico. Thus, a proportion of
SCA36 among ataxia cases in Central and South America is
expected.
Many different mutation types have been identiﬁed in SCAs
(www.scabase.eu). In addition to coding CAG repeats, non-coding
triplet-repeat expansions, as well as larger intronic expansions and
point mutations have been linked to the dominant ataxias (Scho ¨ls
et al., 2004; Sequeiros et al., 2010, 2011). Large repeat expan-
sions are thought to cause disease through haploinsufﬁciency of
the repeat-harbouring gene, or through the generation of RNA
species toxic for the cellular machinery. The NOP56 gene encodes
a 56-kDa protein, which interacts with NOP1 and NOP58 to form
the 60S ribosomal subunit. Alternatively spliced NOP56 isoforms
have not been fully characterized. The GGCCTG repeat expan-
sions in SCA36 lead to the formation of intranuclear RNA foci in
patient’s cells, possibly disrupting the normal function of factors
involved in transcription and splicing (Kobayashi et al., 2011). The
presence of RNA foci has also been reported in other SCAs
(Daughters et al., 2009; Sato et al., 2009), in the myotonic dys-
trophies, Huntington disease-like 2 (Rudnicki et al., 2007) and
more recently a toxic effect on RNA metabolism has also been
proposed for dementia–amyotrophic lateral sclerosis (Renton
et al., 2011), further supporting a wider role of RNA-mediated
mechanisms in neurodegenerative disorders, including those af-
fecting cerebellar, motor neuron and cognitive functions.
The RNA-mediated mechanism of SCA36 may not be limited to
a toxic gain of function. The NOP56 expanded repeat lies next to
the microRNA gene MIR1292, which is downregulated in patient
cells, thus suggesting that a defective regulatory function of
mir1292 might be critical for SCA36 pathogenesis (Kobayashi
et al., 2011). A combination of toxic gain of function and loss
of function mechanisms are being hypothesized for several
neurodegenerative ataxias (Zoghbi and Orr, 2009; Seixas et al.,
2011). It is interesting that TMC2 is a gene located near NOP56.
TMC1 causes dominant and recessive forms of hearing loss
(Kurima et al., 2002). It could be hypothesized that the sensori-
neural hearing loss, almost constant in Galician patients with
SCA36, may be due to dysfunction of TMC2.
In summary, our data add up to the increasing number of neu-
rodegenerative syndromes associated with very large, non-coding
repeat expansions and possible RNA-mediated pathogenesis. We
show that SCA36 is not restricted to the eastern coast of Japan,
but is also present in a European population. Furthermore,
it appears to be the most frequent type of SCA in the Galician
‘Costa da Morte’ ataxia is SCA36 Brain 2012: 135; 1423–1435 | 1433region of Northwest Spain. This description of 44 patients in
10 families contributes to the SCA36 clinical picture, consisting
of a late-onset and slowly progressive, predominantly midline
ataxia, with diverse eye movement abnormalities, sensorineural
hearing loss and mild motor neuron signs, mainly in medullar
territories. We dated the founder mutation responsible for this
geographic cluster to  1275 years ago, indicating that the disease
might have worldwide spread during the last centuries.
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